Erratum to: Tward, J; Lenz, L; Flake II, DD; Rajamani, S; Yonover, P; Olsson, C; Kapoor, DA; Mantz, C; Liauw, SL; Antic, T; Fabrizio, M; Salzstein, D; Shore, N; Albertson, D; Henderson, J; Lee, SP; Gay, HA; Michalski, J; Hung, A; Raben, D; Garraway, I; Lewis, MS; Nguyen, PL; Marshall, DT; Brawer, MK; Stone, S; Cohen, T. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol Biol Phys 2022;113:66-76. doi.org/10.1016/j.ijrobp.2021.09.034
- PMID: 36621237
- DOI: 10.1016/j.ijrobp.2022.09.070
Erratum to: Tward, J; Lenz, L; Flake II, DD; Rajamani, S; Yonover, P; Olsson, C; Kapoor, DA; Mantz, C; Liauw, SL; Antic, T; Fabrizio, M; Salzstein, D; Shore, N; Albertson, D; Henderson, J; Lee, SP; Gay, HA; Michalski, J; Hung, A; Raben, D; Garraway, I; Lewis, MS; Nguyen, PL; Marshall, DT; Brawer, MK; Stone, S; Cohen, T. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol Biol Phys 2022;113:66-76. doi.org/10.1016/j.ijrobp.2021.09.034
Erratum for
-
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):66-76. doi: 10.1016/j.ijrobp.2021.09.034. Epub 2021 Oct 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 34610388
Publication types
LinkOut - more resources
Full Text Sources